NASDAQ
5.08USD
-0.20 (-3.79%)
We have scored 8 news catalysts on NextCure, Inc. (NXTC) over the past 12 months. The biggest single-day move next to one of them came Jul 14, 2026, when NXTC closed +201.8%: “$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC)”. Coverage across the window leans negative (average ticker sentiment −0.22). Most of the impact sits in price momentum and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
18.3M
P/E
—
EPS
—
Beta
1.34
52W range
1.55-15.74
Day range
5.02–5.56
Open
5.18
Prev close
5.28
Volume
71.8K
Avg volume
2.1M
Dividend
0.00
IPO
2019-05-09
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about NextCure, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for NXTC: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
